BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

833 related articles for article (PubMed ID: 19809024)

  • 21. Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes.
    Schroth W; Antoniadou L; Fritz P; Schwab M; Muerdter T; Zanger UM; Simon W; Eichelbaum M; Brauch H
    J Clin Oncol; 2007 Nov; 25(33):5187-93. PubMed ID: 18024866
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A pooled analysis of CYP2D6 genotype in breast cancer prevention trials of low-dose tamoxifen.
    Johansson H; Gandini S; Serrano D; Gjerde J; Lattanzi M; Macis D; Guerrieri-Gonzaga A; Aristarco V; Mellgren G; Lien E; DeCensi A; Bonanni B
    Breast Cancer Res Treat; 2016 Aug; 159(1):97-108. PubMed ID: 27484880
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CYP2D6 genotype is not associated with survival in breast cancer patients treated with tamoxifen: results from a population-based study.
    Hertz DL; Kidwell KM; Hilsenbeck SG; Oesterreich S; Osborne CK; Philips S; Chenault C; Hartmaier RJ; Skaar TC; Sikora MJ; Rae JM
    Breast Cancer Res Treat; 2017 Nov; 166(1):277-287. PubMed ID: 28730340
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacogenomics of tamoxifen therapy.
    Brauch H; Mürdter TE; Eichelbaum M; Schwab M
    Clin Chem; 2009 Oct; 55(10):1770-82. PubMed ID: 19574470
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of CYP2D6*10 on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy.
    Kiyotani K; Mushiroda T; Sasa M; Bando Y; Sumitomo I; Hosono N; Kubo M; Nakamura Y; Zembutsu H
    Cancer Sci; 2008 May; 99(5):995-9. PubMed ID: 18294285
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of the effect of CYP2D6*3, *4,*10, and *17 polymorphisms on the pharmacokinetic of tamoxifen and its metabolites in patients with hormone-positive breast cancer.
    Saghafi F; Salehifar E; Ebrahimi P; Shiran MR; Zaboli E; Sohrevardi SM; Jamialahmadi T; Sahebnasagh A; Sahebkar A
    J Pharm Biomed Anal; 2024 Jan; 238():115839. PubMed ID: 37976989
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of concomitant CYP2D6 inhibitor use and tamoxifen adherence on breast cancer recurrence in early-stage breast cancer.
    Dezentjé VO; van Blijderveen NJ; Gelderblom H; Putter H; van Herk-Sukel MP; Casparie MK; Egberts AC; Nortier JW; Guchelaar HJ
    J Clin Oncol; 2010 May; 28(14):2423-9. PubMed ID: 20385997
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comprehensive CYP2D6 genotype and adherence affect outcome in breast cancer patients treated with tamoxifen monotherapy.
    Thompson AM; Johnson A; Quinlan P; Hillman G; Fontecha M; Bray SE; Purdie CA; Jordan LB; Ferraldeschi R; Latif A; Hadfield KD; Clarke RB; Ashcroft L; Evans DG; Howell A; Nikoloff M; Lawrence J; Newman WG
    Breast Cancer Res Treat; 2011 Jan; 125(1):279-87. PubMed ID: 20809362
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes.
    Goetz MP; Rae JM; Suman VJ; Safgren SL; Ames MM; Visscher DW; Reynolds C; Couch FJ; Lingle WL; Flockhart DA; Desta Z; Perez EA; Ingle JN
    J Clin Oncol; 2005 Dec; 23(36):9312-8. PubMed ID: 16361630
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tamoxifen Pharmacogenetics and Metabolism: Results From the Prospective CYPTAM Study.
    Sanchez-Spitman A; Dezentjé V; Swen J; Moes DJAR; Böhringer S; Batman E; van Druten E; Smorenburg C; van Bochove A; Zeillemaker A; Jongen L; Los M; Neven P; Gelderblom H; Guchelaar HJ
    J Clin Oncol; 2019 Mar; 37(8):636-646. PubMed ID: 30676859
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients.
    Nowell SA; Ahn J; Rae JM; Scheys JO; Trovato A; Sweeney C; MacLeod SL; Kadlubar FF; Ambrosone CB
    Breast Cancer Res Treat; 2005 Jun; 91(3):249-58. PubMed ID: 15952058
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CYP2D6 Genotype Predicts Tamoxifen Discontinuation and Prognosis in Patients With Breast Cancer.
    He W; Grassmann F; Eriksson M; Eliasson E; Margolin S; Thorén L; Hall P; Czene K
    J Clin Oncol; 2020 Feb; 38(6):548-557. PubMed ID: 31800347
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cytochrome P-450 2D6 (CYP2D6) Genotype and Breast Cancer Recurrence in Tamoxifen-Treated Patients: Evaluating the Importance of Loss of Heterozygosity.
    Ahern TP; Hertz DL; Damkier P; Ejlertsen B; Hamilton-Dutoit SJ; Rae JM; Regan MM; Thompson AM; Lash TL; Cronin-Fenton DP
    Am J Epidemiol; 2017 Jan; 185(2):75-85. PubMed ID: 27988492
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients.
    Kiyotani K; Mushiroda T; Imamura CK; Hosono N; Tsunoda T; Kubo M; Tanigawara Y; Flockhart DA; Desta Z; Skaar TC; Aki F; Hirata K; Takatsuka Y; Okazaki M; Ohsumi S; Yamakawa T; Sasa M; Nakamura Y; Zembutsu H
    J Clin Oncol; 2010 Mar; 28(8):1287-93. PubMed ID: 20124171
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance.
    Higgins MJ; Stearns V
    Curr Oncol Rep; 2010 Jan; 12(1):7-15. PubMed ID: 20425602
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Contribution of ABCB1 and CYP2D6 genotypes to the outcome of tamoxifen adjuvant treatment in premenopausal women with breast cancer.
    Argalácsová S; Slanař O; Vítek P; Tesařová P; Bakhouche H; DraŽďáková M; Bartošová O; Zima T; PertuŽelka L
    Physiol Res; 2015; 64(Suppl 4):S539-47. PubMed ID: 26681084
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The CYP2D6*4 polymorphism affects breast cancer survival in tamoxifen users.
    Bijl MJ; van Schaik RH; Lammers LA; Hofman A; Vulto AG; van Gelder T; Stricker BH; Visser LE
    Breast Cancer Res Treat; 2009 Nov; 118(1):125-30. PubMed ID: 19189212
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The rs1800716 variant in CYP2D6 is associated with an increased double endometrial thickness in postmenopausal women on tamoxifen.
    Dieudonné AS; Lambrechts D; Smeets D; Belmans A; Wildiers H; Paridaens R; Hyonil C; Timmerman D; Christiaens MR; Vergote I; Neven P
    Ann Oncol; 2014 Jan; 25(1):90-5. PubMed ID: 24265353
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations.
    Province MA; Goetz MP; Brauch H; Flockhart DA; Hebert JM; Whaley R; Suman VJ; Schroth W; Winter S; Zembutsu H; Mushiroda T; Newman WG; Lee MT; Ambrosone CB; Beckmann MW; Choi JY; Dieudonné AS; Fasching PA; Ferraldeschi R; Gong L; Haschke-Becher E; Howell A; Jordan LB; Hamann U; Kiyotani K; Krippl P; Lambrechts D; Latif A; Langsenlehner U; Lorizio W; Neven P; Nguyen AT; Park BW; Purdie CA; Quinlan P; Renner W; Schmidt M; Schwab M; Shin JG; Stingl JC; Wegman P; Wingren S; Wu AH; Ziv E; Zirpoli G; Thompson AM; Jordan VC; Nakamura Y; Altman RB; Ames MM; Weinshilboum RM; Eichelbaum M; Ingle JN; Klein TE;
    Clin Pharmacol Ther; 2014 Feb; 95(2):216-27. PubMed ID: 24060820
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Influence of CYP2D6 polymorphisms on serum levels of tamoxifen metabolites in Spanish women with breast cancer.
    Zafra-Ceres M; de Haro T; Farez-Vidal E; Blancas I; Bandres F; de Dueñas EM; Ochoa-Aranda E; Gomez-Capilla JA; Gomez-Llorente C
    Int J Med Sci; 2013; 10(7):932-7. PubMed ID: 23781139
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 42.